Results 221 to 230 of about 8,055 (251)

Exercise-induced anaphylaxis with a cofactor of GIP/GLP-1 receptor agonist: A case report. [PDF]

J Allergy Clin Immunol Glob
Chong AC, Elshaer A, Diaz-Menindez M, Squire JD, Wonnaparhown AM, Freeman CM.   +5 more
europepmc   +1 more source

Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis. [PDF]

Endocrinol Diabetes Metab
Kamrul-Hasan ABM, Khalil I, Dutta D, Mahajan K, Nagendra L, Pappachan JM.   +5 more
europepmc   +1 more source

Tirzepatide-Induced Functional Small Bowel Obstruction in a Surgically Naïve Patient: A Case Report. [PDF]

Clin Case Rep
Shimada T, Nose Y, Tojima H, Maehata T, Kato A.   +4 more
europepmc   +1 more source

Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials. [PDF]

Diabetes Obes Metab
Alfaris N, Kushner RF, Li J, Chen KL, Fenimore M, Calderon B, Stefanski A.   +6 more
europepmc   +1 more source

Weight-loss dynamics with tirzepatide versus semaglutide. [PDF]

PNAS Nexus
Venkatakrishnan AJ, Murugadoss K, Soundararajan V.   +2 more
europepmc   +1 more source

Tirzepatide: A Systematic Update

International Journal of Molecular Sciences, 2022
Tirzepatide is a new molecule capable of controlling glucose blood levels by combining the dual agonism of Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptors.
Pasquale Mone, Stanislovas Jankauskas, Gaetano Santulli   +2 more
exaly   +2 more sources